河化股份(000953) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥162,273,039.66, a decrease of 33.36% compared to ¥243,512,663.64 in 2020[20] - The net profit attributable to shareholders for 2021 was ¥10,018,330.39, down 67.62% from ¥30,939,202.60 in the previous year[20] - Basic earnings per share for 2021 were ¥0.03, a decline of 66.67% from ¥0.09 in 2020[21] - The net cash flow from operating activities decreased by 90.00%, amounting to ¥6,710,748.57 compared to ¥67,130,814.12 in 2020[21] - The company reported a total of ¥7.72 million in non-recurring gains and losses for 2021, a significant recovery from a loss of approximately ¥7.54 million in 2020[27] - The company achieved a total operating revenue of ¥162,273,039.66 in 2021, a decrease of 33.36% compared to the previous year[43] - The net profit attributable to shareholders was ¥10,018,330.39, down 67.62% year-on-year[43] - The pharmaceutical intermediates segment generated ¥89,702,497.45, accounting for 55.28% of total revenue, reflecting a 41.67% decline from 2020[45] - The fertilizer business contributed ¥68,291,410.11, representing 42.08% of total revenue, with a decrease of 22.49% year-on-year[45] Business Transformation and Strategy - The company has undergone a significant business transformation since 2020, shifting its focus to the research, production, and sales of chemical raw materials and pharmaceuticals[18] - The company emphasizes the importance of market conditions in achieving its operational goals and future plans[4] - The company is focused on the R&D and production of pharmaceutical intermediates, with a strong emphasis on new product development and process improvement[35] - The company utilizes a centralized procurement model to improve cost efficiency and reduce supply chain volatility[37] - The production strategy includes both general production based on sales forecasts and customized production according to client specifications[37] Market and Demand - The demand for chloroquine side chains surged in 2020 due to the COVID-19 pandemic, leading to increased product demand and prices, although the market normalized in 2021[32] - The company faced challenges due to high raw material prices and unstable energy supply, impacting production cycles and costs[42] - The domestic revenue was ¥112,500,990.05, down 31.98% year-on-year, while overseas revenue decreased by 36.28% to ¥49,772,049.61[45] Research and Development - The company’s R&D expenses in 2021 were ¥7,703,278.92, a decrease of 9.24% compared to ¥8,487,368.41 in 2020, while the R&D expenses accounted for 4.75% of operating revenue[56] - The company completed the optimization of several new processes, including methyl silane and valproic acid, aiming for industrial production and new economic growth points[56][57] - The number of R&D personnel decreased by 7.14% from 56 in 2020 to 52 in 2021, while the proportion of R&D personnel increased from 27.18% to 32.53%[57] Governance and Compliance - The company has established a robust internal management system to ensure compliance with laws and regulations, enhancing governance standards[82] - The company prioritizes transparent information disclosure, ensuring all shareholders have equal access to relevant information[85] - The company actively manages investor relations through various communication channels, fostering a positive relationship with investors[85] - The company has maintained effective internal control over financial reporting without any significant deficiencies or important deficiencies[129] - The internal control audit report issued on April 30, 2022, confirmed that the company maintained effective internal controls in all material respects as of December 31, 2021[134] Shareholder Relations - The company held two shareholder meetings during the reporting period, ensuring equal rights for all shareholders, particularly minority shareholders[83] - The annual shareholders' meeting had a participation rate of 30.29% on May 18, 2021[88] - The first extraordinary shareholders' meeting had a participation rate of 43.76% on September 14, 2021[89] - The company has not reported any penalties from securities regulatory agencies for its current and recently departed directors, supervisors, and senior management[108] Environmental and Social Responsibility - The company has invested in environmental protection facilities and improved production processes to achieve energy conservation and emission reduction goals[147] - The company has not faced any administrative penalties related to environmental issues during the reporting period[145] - The company has not initiated any poverty alleviation or rural revitalization projects during the reporting period[148] Future Outlook - The company plans to enhance cooperation with downstream pharmaceutical clients and increase investment in technology development and business expansion[74] - New product development will focus on T51, T22, and T62 intermediates, with efforts to accelerate their market introduction[75] - The company anticipates risks from drug procurement policies that may lead to price declines for intermediate products, prompting a need for cost control and quality improvement[77] - The company has provided a revenue guidance of CNY 1.8 billion for the fiscal year 2022, which reflects an expected growth of 20%[95] Related Party Transactions and Commitments - The company has committed to avoid any form of fund occupation or illegal appropriation of assets from the listed company[153] - The company has pledged to ensure that no direct or indirect means will be used to seek control over the board of directors of the listed company[153] - The commitments made by the actual controller will remain valid unless they cease to be the controlling shareholder[150] - The company has undertaken to minimize related transactions and ensure they are conducted at market prices[150] Employee and Management Information - The total number of employees at the end of the reporting period is 182, with 16 in the parent company and 166 in major subsidiaries[122] - The company has a complete business operation system and does not engage in substantial competition with its controlling shareholders[87] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 2.0772 million CNY[111]